Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size, Report 2032

Published Date : 28 Sep 2023

The global chronic obstructive pulmonary disease (COPD) treatment market size surpassed USD 18.1 billion in 2022 and it is expected to rake around USD 29.88 billion by 2032, poised to grow at a CAGR of 5.14% during the forecast period 2023 to 2032.

Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Growth Rate from 2023 To 2032

Factors such as the increasing prevalence of COPD, advancements in COPD treatments, growing awareness, increasing healthcare expenditure, government initiatives and technological advancements are driving the market. However, the high cost of treatment, side effects and complications, alternative treatments, and regulatory challenges obstruct the market.

Regional Landscape:

Europe is estimated to grow faster during the forecast period. It is a significant market for COPD treatment, with countries such as Germany, France, and the UK significant contributors to the market's growth. The region’s growth is due to the high prevalence of COPD, the increase in the geriatric population, technological advancements, a favourable regulatory environment, and increasing awareness about COPD. COPD is a major public health concern in Europe, with an estimated 44 million people diagnosed with the disease.

This high prevalence of COPD is driving the demand for COPD treatment in the region. The aging population in Europe is contributing to the growth of the COPD treatment market. Older adults are at a higher risk of developing COPD, and with the ageing population, the demand for COPD treatment is expected to increase.

Moreover, Europe is a hub for technological advancements in healthcare, including developing advanced drugs and devices for COPD treatment. Adopting advanced technologies is expected to improve the quality of COPD treatment and drive the market's growth. The regulatory environment in Europe is favorable for the growth of the COPD treatment market. The European Medicines Agency (EMA) has approved several drugs for treating COPD, providing patients access to effective treatment options. Furthermore, there is a growing awareness of COPD in Europe, leading to increased diagnosis and treatment of the disease. This increasing awareness is expected to drive the demand for COPD treatment in the region.

Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Report Scope:

Report Coverage Details
Market Revenue in 2023 USD 19.03 Billion
Projected Forecast Revenue by 2032 USD 29.88 Billion
Growth Rate from 2023 to 2032 CAGR of 5.14%
Largest Market North America
Base Year 2022
Forecast Period 2023 to 2032
Regions Covered North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

Market Dynamics:


Advancements in treatment options

Over the years, there have been significant advancements in the treatment options available for COPD, including new medications, inhalers, nebulizers, oxygen therapy equipment, and pulmonary rehabilitation programs. New medications for COPD, such as bronchodilators and inhaled corticosteroids, have been developed to improve lung function and reduce symptoms. These medications work by relaxing the muscles around the airways and reducing lung inflammation. They are delivered via inhalers, which are easy to use and convenient for patients.

In addition to medications, there have been advancements in medical devices used for COPD treatment. Nebulizers convert liquid medication into a fine mist that can be inhaled directly into the lungs. They are often used for patients who have difficulty using inhalers or require a higher dose of medication. Oxygen therapy is also an important treatment option for COPD patients. It involves using a portable oxygen tank or concentrator to deliver oxygen to the lungs, which improves breathing and reduces fatigue.

Pulmonary rehabilitation programs are another treatment option that has seen advancements in recent years. These programs combine exercise, breathing techniques, and education to improve lung function and reducing symptoms in COPD patients. Therefore, the advances in treatment options for COPD are enhancing the effectiveness of COPD treatment and increasing the quality of life for COPD patients. This is expected to drive the growth of the COPD treatment market in the coming years as more patients seek out these new treatment options.


Poor adherence to treatment by patients

COPD treatment often involves multiple medications and medical devices, and patients struggle to adhere to their treatment regimen. Poor adherence leads to ineffective treatment and worsening symptoms, impacting patient outcomes and quality of life. Several factors contribute to poor adherence, including medication side effects, difficulty using medical devices, and forgetfulness. In addition, some patients struggle to afford their medication or have limited access to healthcare resources, further impacting their ability to adhere to their treatment regimen. Poor adherence also affects healthcare systems and payers, increasing healthcare costs due to hospitalizations and other medical interventions.

In addition, poor adherence also leads to treatment failure and disease progression, which further limits patient access to care and impacts patient outcomes. Therefore, poor adherence to COPD treatment significantly restricts the growth of the COPD treatment market.


Growing focus on personalized medicine and precision therapies.

Personalized medicine involves tailoring treatments to individual patients based on their unique genetic, environmental, and lifestyle factors. In the context of COPD, personalized medicine involves identifying specific biomarkers or genetic factors contributing to the disease and using this information to develop targeted treatments. Precision therapies are also becoming increasingly crucial in COPD treatment. These therapies involve using advanced technologies, such as gene editing and cell therapies, to develop more targeted and effective treatments for the disease.

The growing focus on personalized medicine and precision therapies presents significant opportunities for the COPD treatment market. These approaches potentially improve patient outcomes and reduce healthcare costs by providing more effective and targeted treatments. In addition, using personalized medicine and precision therapies help address some of the current limitations of COPD treatment, such as poor adherence and limited treatment options.

By tailoring treatments to individual patients, it may be possible to improve patient outcomes and reduce the disease burden. Thus, the growing focus on personalized medicine and precision therapies is a significant opportunity for the COPD treatment market. Investing in research and development in this area is expected to drive growth and improve patient outcomes in the future.

COVID-19 Impact:

COVID-19 adversely impacted the market. One significant adverse impact is the disruption of healthcare services, including diagnosing and treating COPD. The pandemic has overwhelmed healthcare systems, and healthcare workers diverted to COVID-19 care, leading to delays and cancellations of non-emergency procedures and appointments. This disruption has significantly impacted COPD patients, who experience worsening symptoms and a decline in their overall health without timely access to healthcare services.

In addition, the pandemic has reduced funding for research and development, which has delayed the development of new and innovative treatments for COPD. Moreover, the pandemic has resulted in a global economic recession, leading to reduced funding for healthcare systems and a decrease in demand for non-COVID-19-related healthcare services. This results in a reduction in investment in the COPD treatment market and a decrease in the availability of resources for managing and treating COPD.

Drug Class Landscape:

The bronchodilators segment is estimated to grow faster during the forecast period. Bronchodilators are medications that work by relaxing the airways’ muscles, allowing for improved airflow to the lungs. There are two types of bronchodilators: short-acting and long-acting. Short-acting bronchodilators are used for immediate relief of COPD symptoms, while long-acting bronchodilators are used for long-term disease management.

The growing demand for bronchodilators is attributed to several factors, such as the increasing prevalence of COPD worldwide, rising awareness of the disease among patients and healthcare providers, and the availability of new and more effective bronchodilator medications. In addition, the development of combination therapies that include bronchodilators is also expected to drive growth in this segment. Bronchodilators are widely used to treat COPD and are essential to most COPD treatment regimens. As such, the bronchodilators segment of the COPD treatment market is expected to experience continued growth in the coming years.

Type Landscape:

The emphysema segment is estimated to grow faster during the forecast period. The Emphysema segment of the COPD treatment market is growing due to several factors. The aging population is at an increased risk of developing emphysema, which is typically diagnosed in people over the age of 50. As the population ages, the incidence of emphysema is expected to rise, driving growth in the Emphysema segment of the COPD treatment market.  Moreover, there is growing awareness of the disease among patients and healthcare providers, leading to earlier diagnosis and treatment. Early diagnosis and treatment help slow the disease's progression and improve patient outcomes.

Furthermore, there is ongoing research and development in COPD treatment, focusing on developing new and more effective medications and therapies for emphysema. For instance, new therapies that target specific pathways involved in the development and progression of the disease, such as stem cell therapy and gene therapy, are being developed and tested in clinical trials. These new therapies hold promise for improving outcomes for patients with emphysema and are expected to drive growth in the Emphysema segment of the COPD treatment market.

Distribution Channel Landscape:

The hospital segment is expected to grow faster during the forecast period. The growth of this segment is due to several factors. Patients with severe COPD often require hospitalization, making hospital pharmacies a significant source of COPD medications. Hospital pharmacies are staffed by trained professionals who ensure patients receive the right medication at the right time and dose.

Moreover, hospital pharmacies often have many COPD medications on-site, benefiting patients with complex medication regimens. This reduces the need for patients to visit multiple pharmacies to fill their prescriptions. Hospital pharmacies are an important distribution channel for specialty COPD medications, such as biologics and inhalation therapies, which require special handling and storage.

Furthermore, hospitals are increasingly implementing strategies to improve medication management and patient outcomes, including optimising COPD medication use. This leads to increased demand for COPD medications from hospital pharmacies. Therefore, the growing demand for COPD medications in hospital settings, the availability of a wide range of COPD medications, the importance of hospital pharmacies in distributing specialty medications, and the increasing focus on medication management and patient outcomes are all contributing to the growth of the Hospital Pharmacies segment in the COPD treatment market.

Recent Developments:

  • In Jan 2022, AstraZeneca announced its completion of the transfer of global rights for Eklira and Duaklir to Covis Pharma completed.
  • In September 2019, Novartis announced the positive results from the Phase III IRIDIUM study of inhaled combination QVM149 in patients with uncontrolled asthma.

Major Key Players:

  • GlaxoSmithKline (GSK)
  • AstraZeneca
  • Boehringer Ingelheim
  • Novartis
  • Teva Pharmaceuticals
  • Pfizer
  • Mylan
  • Chiesi
  • Roche
  • Merck & Co.

Market Segmentation:

By Drug Class

  • Combination Therapy
  • Bronchodilators
  • Corticosteroids
  • Phosphodiester Type 4 Inhibitor
  • Mucokinetics
  • Others

By Type

  • Chronic Bronchitis
  • Emphysema

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Buy this Research Report@

You can place an order or ask any questions, please feel free to contact at | +1 9197 992 333